Product Information
AZITHROMYCIN 200 MG/5 ML SUSP is a generic product labeled by Chartwell RX LLC, priced at $0.2046 per ML under NDC 62135070543. Its NADAC has been published 82 times since Mar 12, 2025.
FDA first approved this application on May 15, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/5mL
Manufacturer
Chartwell RX LLCNDC
62135070543
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AZITHROMYCIN MONOHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA065488FDA Approved
5/15/2015
TE Code
AB
On Market Since
5/15/2015
Pharmacological Classes
Price Statistics
The NADAC for AZITHROMYCIN 200 MG/5 ML SUSP has been published 82 times since Mar 12, 2025, and over the history we have for it it has declined 6.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2046 per ML |
|---|---|
| All-time high | $0.2329 (May 14, 2025) |
| All-time low | $0.2046 (Sep 23, 2026) |
| 52-week high | $0.2206 |
| 52-week low | $0.2046 |
| Median price | $0.2175 |
| Average price | $0.2190 |
| Largest weekly change | +3.6% (Mar 19, 2025) |
| Weeks tracked | 82 |
| Tracking since | Mar 12, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Azithromycin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Azithromycin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AZITHROMYCIN 200 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for AZITHROMYCIN 200 MG/5 ML SUSP, manufactured by Chartwell RX LLC, is $0.2046 per ML (NDC 62135070543), effective Sep 30, 2026.
How has the price of AZITHROMYCIN 200 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for AZITHROMYCIN 200 MG/5 ML SUSP has declined 6.4%. It has been tracked across 82 weekly CMS publications since Mar 12, 2025.
What are the highest and lowest recorded NADAC prices for AZITHROMYCIN 200 MG/5 ML SUSP?
Since Mar 12, 2025, the NADAC for AZITHROMYCIN 200 MG/5 ML SUSP has ranged from a low of $0.2046 (Sep 23, 2026) to a high of $0.2329 (May 14, 2025), with a median of $0.2175 per ML.
Are there cheaper alternatives to AZITHROMYCIN 200 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of AZITHROMYCIN 200 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AZITHROMYCIN 200 MG/5 ML SUSP?
AZITHROMYCIN 200 MG/5 ML SUSP (NDC 62135070543) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.